Securities Code: 002932 Securities Abbreviation: Mindray Bio-Medical Announcement No.: 2026-026 Wuhan Mindray Bio-Medical Electronics Co., Ltd. Announcement on the Proposed Profit Distribution Plan for 2025 The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.
I. Deliberation Procedures On April 20, 2026, the fifth meeting of the fifth Board of Directors of the Company deliberated and approved the "Proposal on the Profit Distribution Plan for 2025" and agreed to submit this profit distribution plan to the Company's Shareholders' Meeting for deliberation.
II. Basic Situation of the 2025 Profit Distribution Plan According to the audit by Lixin Certified Public Accountants (Special General Partnership), the Company's consolidated net profit attributable to shareholders of the listed company in 2025 was -16,460,699.59 yuan, and the net profit of the parent company in 2025 was 53,923,380.63 yuan. As of December 31, 2025, the distributable profit in the Company's consolidated statements was 4,103,381,789.04 yuan, of which the distributable profit of the parent company was 3,951,741,564.77 yuan. Based on the Company's financial situation, the proposed profit distribution plan for 2025 is: no cash dividend, no bonus shares, and no capital reserve to bonus share conversion.
III. Specifics of the Cash Dividend Plan
- The Company's 2025 Cash Dividend Plan Does Not Involve Other Risk Warning Situations